查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1298398

支原體檢測市場：按產品、按技術、按應用、按最終用戶：2023-2032 年全球機會分析和行業預測

Mycoplasma Testing Market By Product, By Technology, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 400 Pages | 商品交期: 2-3個工作天內

價格

支原體檢測市場規模到2022年將達到7億美元，預計到2032年將達到22.431億美元，2023年至2032年復合年增長率為11.7%。

Mycoplasma Testing Market-IMG1

支原體檢測用於檢測細胞培養樣品中是否存在支原體污染。支原體是一種沒有細胞壁的細菌，因此很難檢測到並從細胞培養物中去除。支原體污染會導致細胞培養中出現各種問題，例如生長特性的改變、基因表達的改變以及實驗結果的惡化。因此，必須定期檢查細胞培養物是否有支原體污染，以確保實驗結果的準確性和可靠性。支原體檢測在疫苗、病毒培養物和其他生物製藥的檢測過程中非常重要。

支原體檢測市場的增長是由於對生物製品和生物仿製藥的需求不斷增加、細胞培養物污染病例激增以及藥物開發新技術的日益採用推動的。生物製劑和生物仿製藥是使用活細胞製造的複雜藥物，在製造過程中可能會被支原體污染。因此，美國食品藥品監督管理局（FDA）和歐洲藥品管理局（EMA）等監管機構要求生物製劑和生物仿製藥在批准使用前必須進行支原體污染測試。因此，支原體檢測服務的需求猛增。例如，根據IQVIA關於2021年歐洲生物仿製藥競爭影響的報告，2020年批准了大約9種生物仿製藥，2021年批准了7種生物仿製藥。因此，對生物製劑和生物仿製藥的批准和需求的增加導致了支原體檢測需求的增加。

此外，生物製藥行業細胞培養污染髮生率的增加和臨床試驗的全球化是推動市場增長的主要因素。由於臨床試驗在多個國家和地區進行，因此需要支原體檢測服務來保證試驗參與者的安全和試驗數據的準確性。這增加了對支原體檢測服務和滿足標準化檢測要求的產品的需求。

然而，支原體檢測產品的高成本限制了生物製藥公司的採用，從而限制了市場的增長。例如，SouthernBiotech的Mycoplasma Detection Kit，用於檢測細胞培養物中的支原體污染，價格約為200-230美元。此外，基於培養的支原體檢測服務的價格約為每個樣本 250-300 美元。因此，支原體檢測產品和服務的高成本對市場增長產生負面影響。

另一方面，美國、德國和中國等發達國家和新興國家對支原體檢測的需求不斷增加，預計將在預測期內為支原體檢測市場帶來巨大的商機。

支原體檢測市場按產品、技術、應用、最終用戶和地區細分。在產品基礎上，市場分為儀器、試劑盒和試劑以及服務。從技術角度來看，市場分為 PCR、ELISA、微生物培養和□法。按用途分為細胞系檢測、病毒檢測、生產末端細胞檢測等。按最終用戶劃分，可分為學術研究機構、細胞庫、合同研究機構、製藥和生物技術公司等。

目錄

第 1 章 簡介

第二章執行摘要

第三章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資口袋
  • 波特五力分析
    • 供應商的議價能力
    • 買方議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭強度
  • 市場動態
    • 推動力
      • 支原體檢測需求快速增長
      • 細胞培養物污染增加
    • 阻礙因素
      • 支原體檢測試劑盒和檢測設備成本較高
    • 機會
      • 新興經濟體提供了豐厚的機遇
      • 不斷進步的技術進步
  • COVID-19 市場影響分析

4 支原體檢測市場，分產品

  • 概述
    • 市場規模及預測
  • 機器
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 試劑盒和試劑
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 服務
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類

5 支原體檢測市場（按技術）

  • 概述
    • 市場規模/預測
  • PCR市場
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • ELISA法
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 微生物培養技術
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • □法
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類

6 支原體檢測市場（按應用）

  • 概述
    • 市場規模及預測
  • 細胞系測試
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 病毒測試
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 生產結束電池測試
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類

7 支原體測試市場（按最終用戶）

  • 概述
    • 市場規模及預測
  • 學術研究所
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 細胞庫
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 合同研究組織
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 製藥和生物技術公司
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類

8 支原體檢測市場（按地區）

  • 概述
    • 市場規模/預測：按地區
  • 北美
    • 主要趨勢和機遇
    • 市場規模/預測：按產品分類
    • 市場規模/預測：按技術
    • 市場規模/預測：按應用
    • 市場規模/預測：按最終用戶分類
    • 市場規模/預測：按國家
      • 美國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按產品分類
      • 市場規模/預測：按技術
      • 市場規模/預測：按應用
      • 市場規模/預測：按最終用戶分類
      • 加拿大
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按產品分類
      • 市場規模/預測：按技術
      • 市場規模/預測：按應用
      • 市場規模/預測：按最終用戶分類
      • 墨西哥
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按產品分類
      • 市場規模/預測：按技術
      • 市場規模/預測：按應用
      • 市場規模/預測：按最終用戶分類
  • 歐洲
    • 主要趨勢和機遇
    • 市場規模/預測：按產品分類
    • 市場規模/預測：按技術
    • 市場規模/預測：按應用
    • 市場規模/預測：按最終用戶分類
    • 市場規模/預測：按國家
      • 德國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按產品分類
      • 市場規模/預測：按技術
      • 市場規模/預測：按應用
      • 市場規模/預測：按最終用戶分類
      • 法國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按產品分類
      • 市場規模/預測：按技術
      • 市場規模/預測：按應用
      • 市場規模/預測：按最終用戶分類
      • 英國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按產品分類
      • 市場規模/預測：按技術
      • 市場規模/預測：按應用
      • 市場規模/預測：按最終用戶分類
      • 意大利
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按產品分類
      • 市場規模/預測：按技術
      • 市場規模/預測：按應用
      • 市場規模/預測：按最終用戶分類
      • 西班牙
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按產品分類
      • 市場規模/預測：按技術
      • 市場規模/預測：按應用
      • 市場規模/預測：按最終用戶分類
      • 歐洲其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按產品分類
      • 市場規模/預測：按技術
      • 市場規模/預測：按應用
      • 市場規模/預測：按最終用戶分類
  • 亞太地區
    • 主要趨勢和機遇
    • 市場規模/預測：按產品分類
    • 市場規模/預測：按技術
    • 市場規模/預測：按應用
    • 市場規模/預測：按最終用戶分類
    • 市場規模/預測：按國家
      • 日本
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按產品分類
      • 市場規模/預測：按技術
      • 市場規模/預測：按應用
      • 市場規模/預測：按最終用戶分類
      • 中國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按產品分類
      • 市場規模/預測：按技術
      • 市場規模/預測：按應用
      • 市場規模/預測：按最終用戶分類
      • 澳大利亞
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按產品分類
      • 市場規模/預測：按技術
      • 市場規模/預測：按應用
      • 市場規模/預測：按最終用戶分類
      • 印度
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按產品分類
      • 市場規模/預測：按技術
      • 市場規模/預測：按應用
      • 市場規模/預測：按最終用戶分類
      • 韓國市場
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按產品分類
      • 市場規模/預測：按技術
      • 市場規模/預測：按應用
      • 市場規模/預測：按最終用戶分類
      • 亞太其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按產品分類
      • 市場規模/預測：按技術
      • 市場規模/預測：按應用
      • 市場規模/預測：按最終用戶分類
  • 拉丁美洲/中東/非洲
    • 主要趨勢和機遇
    • 市場規模/預測：按產品分類
    • 市場規模/預測：按技術
    • 市場規模/預測：按應用
    • 市場規模/預測：按最終用戶分類
    • 市場規模/預測：按國家
      • 巴西
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按產品分類
      • 市場規模/預測：按技術
      • 市場規模/預測：按應用
      • 市場規模/預測：按最終用戶分類
      • 沙特阿拉伯
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按產品分類
      • 市場規模/預測：按技術
      • 市場規模/預測：按應用
      • 市場規模/預測：按最終用戶分類
      • 南非
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按產品分類
      • 市場規模/預測：按技術
      • 市場規模/預測：按應用
      • 市場規模/預測：按最終用戶分類
      • 其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按產品分類
      • 市場規模/預測：按技術
      • 市場規模/預測：按應用
      • 市場規模/預測：按最終用戶分類

第9章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10大公司產品圖
  • 比賽儀表板
  • 比賽熱圖
  • 2022 年頂級公司定位

第十章公司簡介

  • Thermo Fisher Scientific Inc.
  • Charles River Laboratories
  • Lonza
  • F. Hoffmann-La Roche Ltd.
  • Bio-Rad Laboratories, Inc.
  • Eurofins Scientific
  • ATCC
  • Bionique Testing Laboratories LLC
  • InvivoGen
  • Norgen Biotek Corp.
Product Code: A11266

The Mycoplasma Testing Market was valued at $0.7 billion in 2022 and is estimated to reach $2,243.10 million by 2032, exhibiting a CAGR of 11.7% from 2023 to 2032.

Mycoplasma Testing Market - IMG1

Mycoplasma testing is used to detect the presence of mycoplasma contamination in cell culture samples. Mycoplasma is a type of bacteria that lacks a cell wall and is difficult to detect and remove from cell cultures. Mycoplasma contamination can cause various problems in cell cultures, such as altered growth characteristics, changes in gene expression, and compromised experimental results. Therefore, it is essential to regularly test cell cultures for mycoplasma contamination to ensure the accuracy and reliability of experimental results. Mycoplasma testing is important in the process of testing vaccines, virus cultures, and other biopharmaceuticals.

The mycoplasma testing market growth is driven by an increase in demand for biologics & biosimilars, a surge in incidences of cell culture contamination, and a rise in the adoption of novel technologies for drug development. Biologics and biosimilars are complex drugs produced using living cells, and they can be contaminated by mycoplasma during the manufacturing process. Thus, regulatory bodies such as Food and Drug Administration (FDA) and European Medicines Agency (EMA) require biologics and biosimilars to be tested for mycoplasma contamination before they are approved for use. This has created a surge in demand for mycoplasma testing services. For instance, according to the IQVIA report on the Impact of Biosimilar Competition in Europe in 2021, about 9 biosimilars were approved in 2020 and 7 approved in 2021. Thus, the rise in the approval and demand for biologics & biosimilars has resulted in increased demand for mycoplasma testing.

Furthermore, the rise in incidences of cell culture contamination in the biopharmaceutical industry and the globalization of clinical trials are the key factors that boost market growth. As clinical trials are conducted across multiple countries and regions, there is a need for mycoplasma testing services that can ensure the safety of trial participants and the accuracy of trial data. This has led to an increasing demand for mycoplasma testing services and products that meet standardized testing requirements.

However, the high cost of mycoplasma testing products limits their adoption in biopharmaceutical companies, which, in turn, restrains the market growth. For instance, the cost of SouthernBiotech's Mycoplasma Detection Kit used for the detection of mycoplasma contamination in cell cultures is around $200-230. In addition, the price of culture-based mycoplasma testing service is about $250-300 per sample. Thus, the high cost of mycoplasma testing products and services negatively impacts market growth.

On the other hand, the increase in demand for mycoplasma testing in developed and developing countries such as U.S., Germany, and China is expected to create immense opportunities for the mycoplasma testing market during the forecast period.

The mycoplasma testing market is segmented on the basis of product, technology, application, end-user, and region. On the basis of product, the market is categorized into instruments, kits & reagents, and services. On the basis of technology, the market is divided into PCR, ELISA, microbial culture techniques, and enzymatic methods. On the basis of application, the market is classified into cell line testing, virus testing, end-of-production cell testing, and others. On the basis of end users, the market is segregated into academic research institutes, cell banks, contract research organizations, pharmaceutical & biotechnology companies, and others.

Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and the rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Major key players that operate in the global mycoplasma testing market are: ATCC, Bionique Testing Laboratories LLC, Bio-Rad Laboratories, Inc., Charles River Laboratories, Eurofins Scientific, F. Hoffmann-La Roche Ltd., InvivoGen, Lonza, Norgen Biotek Corp., and Thermo Fisher Scientific Inc. Key players operating in the market have adopted product approval, acquisition, and product launch as their key strategies to expand their product portfolio.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the mycoplasma testing market analysis from 2022 to 2032 to identify the prevailing mycoplasma testing market opportunities.
  • Market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
  • An in-depth analysis of the mycoplasma testing market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes analysis of the regional as well as global mycoplasma testing market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product

  • Instruments
  • Kits and Reagents
  • Services

By Technology

  • PCR
  • ELISA
  • Microbial Culture Techniques
  • Enzymatic Methods

By Application

  • Cell Line Testing
  • Virus Testing
  • End of Production Cells Testing
  • Others

By End User

  • Academic Research Institutes
  • Cell Banks
  • Contract Research Organizations
  • Pharmaceutical and Biotechnology Companies
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • ATCC
    • Bionique Testing Laboratories LLC
    • Bio-Rad Laboratories, Inc.
    • Charles River Laboratories
    • Eurofins Scientific
    • F. Hoffmann-La Roche Ltd.
    • InvivoGen
    • Lonza
    • Norgen Biotek Corp.
    • Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Surge in demand for mycoplasma testing
      • 3.4.1.2. Increase in incidences of cell culture contamination
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of mycoplasma testing kits and instruments
    • 3.4.3. Opportunities
      • 3.4.3.1. Developing economies offer lucrative opportunities
      • 3.4.3.2. Rise in technological advancements
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: MYCOPLASMA TESTING MARKET, BY PRODUCT

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Instruments
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Kits and Reagents
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Services
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: MYCOPLASMA TESTING MARKET, BY TECHNOLOGY

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. PCR
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. ELISA
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Microbial Culture Techniques
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Enzymatic Methods
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: MYCOPLASMA TESTING MARKET, BY APPLICATION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Cell Line Testing
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Virus Testing
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. End of Production Cells Testing
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country
  • 6.5. Others
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by region
    • 6.5.3. Market share analysis by country

CHAPTER 7: MYCOPLASMA TESTING MARKET, BY END USER

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Academic Research Institutes
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by region
    • 7.2.3. Market share analysis by country
  • 7.3. Cell Banks
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by region
    • 7.3.3. Market share analysis by country
  • 7.4. Contract Research Organizations
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by region
    • 7.4.3. Market share analysis by country
  • 7.5. Pharmaceutical and Biotechnology Companies
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by region
    • 7.5.3. Market share analysis by country
  • 7.6. Others
    • 7.6.1. Key market trends, growth factors and opportunities
    • 7.6.2. Market size and forecast, by region
    • 7.6.3. Market share analysis by country

CHAPTER 8: MYCOPLASMA TESTING MARKET, BY REGION

  • 8.1. Overview
    • 8.1.1. Market size and forecast By Region
  • 8.2. North America
    • 8.2.1. Key trends and opportunities
    • 8.2.2. Market size and forecast, by Product
    • 8.2.3. Market size and forecast, by Technology
    • 8.2.4. Market size and forecast, by Application
    • 8.2.5. Market size and forecast, by End User
    • 8.2.6. Market size and forecast, by country
      • 8.2.6.1. U.S.
      • 8.2.6.1.1. Key market trends, growth factors and opportunities
      • 8.2.6.1.2. Market size and forecast, by Product
      • 8.2.6.1.3. Market size and forecast, by Technology
      • 8.2.6.1.4. Market size and forecast, by Application
      • 8.2.6.1.5. Market size and forecast, by End User
      • 8.2.6.2. Canada
      • 8.2.6.2.1. Key market trends, growth factors and opportunities
      • 8.2.6.2.2. Market size and forecast, by Product
      • 8.2.6.2.3. Market size and forecast, by Technology
      • 8.2.6.2.4. Market size and forecast, by Application
      • 8.2.6.2.5. Market size and forecast, by End User
      • 8.2.6.3. Mexico
      • 8.2.6.3.1. Key market trends, growth factors and opportunities
      • 8.2.6.3.2. Market size and forecast, by Product
      • 8.2.6.3.3. Market size and forecast, by Technology
      • 8.2.6.3.4. Market size and forecast, by Application
      • 8.2.6.3.5. Market size and forecast, by End User
  • 8.3. Europe
    • 8.3.1. Key trends and opportunities
    • 8.3.2. Market size and forecast, by Product
    • 8.3.3. Market size and forecast, by Technology
    • 8.3.4. Market size and forecast, by Application
    • 8.3.5. Market size and forecast, by End User
    • 8.3.6. Market size and forecast, by country
      • 8.3.6.1. Germany
      • 8.3.6.1.1. Key market trends, growth factors and opportunities
      • 8.3.6.1.2. Market size and forecast, by Product
      • 8.3.6.1.3. Market size and forecast, by Technology
      • 8.3.6.1.4. Market size and forecast, by Application
      • 8.3.6.1.5. Market size and forecast, by End User
      • 8.3.6.2. France
      • 8.3.6.2.1. Key market trends, growth factors and opportunities
      • 8.3.6.2.2. Market size and forecast, by Product
      • 8.3.6.2.3. Market size and forecast, by Technology
      • 8.3.6.2.4. Market size and forecast, by Application
      • 8.3.6.2.5. Market size and forecast, by End User
      • 8.3.6.3. UK
      • 8.3.6.3.1. Key market trends, growth factors and opportunities
      • 8.3.6.3.2. Market size and forecast, by Product
      • 8.3.6.3.3. Market size and forecast, by Technology
      • 8.3.6.3.4. Market size and forecast, by Application
      • 8.3.6.3.5. Market size and forecast, by End User
      • 8.3.6.4. Italy
      • 8.3.6.4.1. Key market trends, growth factors and opportunities
      • 8.3.6.4.2. Market size and forecast, by Product
      • 8.3.6.4.3. Market size and forecast, by Technology
      • 8.3.6.4.4. Market size and forecast, by Application
      • 8.3.6.4.5. Market size and forecast, by End User
      • 8.3.6.5. Spain
      • 8.3.6.5.1. Key market trends, growth factors and opportunities
      • 8.3.6.5.2. Market size and forecast, by Product
      • 8.3.6.5.3. Market size and forecast, by Technology
      • 8.3.6.5.4. Market size and forecast, by Application
      • 8.3.6.5.5. Market size and forecast, by End User
      • 8.3.6.6. Rest of Europe
      • 8.3.6.6.1. Key market trends, growth factors and opportunities
      • 8.3.6.6.2. Market size and forecast, by Product
      • 8.3.6.6.3. Market size and forecast, by Technology
      • 8.3.6.6.4. Market size and forecast, by Application
      • 8.3.6.6.5. Market size and forecast, by End User
  • 8.4. Asia-Pacific
    • 8.4.1. Key trends and opportunities
    • 8.4.2. Market size and forecast, by Product
    • 8.4.3. Market size and forecast, by Technology
    • 8.4.4. Market size and forecast, by Application
    • 8.4.5. Market size and forecast, by End User
    • 8.4.6. Market size and forecast, by country
      • 8.4.6.1. Japan
      • 8.4.6.1.1. Key market trends, growth factors and opportunities
      • 8.4.6.1.2. Market size and forecast, by Product
      • 8.4.6.1.3. Market size and forecast, by Technology
      • 8.4.6.1.4. Market size and forecast, by Application
      • 8.4.6.1.5. Market size and forecast, by End User
      • 8.4.6.2. China
      • 8.4.6.2.1. Key market trends, growth factors and opportunities
      • 8.4.6.2.2. Market size and forecast, by Product
      • 8.4.6.2.3. Market size and forecast, by Technology
      • 8.4.6.2.4. Market size and forecast, by Application
      • 8.4.6.2.5. Market size and forecast, by End User
      • 8.4.6.3. Australia
      • 8.4.6.3.1. Key market trends, growth factors and opportunities
      • 8.4.6.3.2. Market size and forecast, by Product
      • 8.4.6.3.3. Market size and forecast, by Technology
      • 8.4.6.3.4. Market size and forecast, by Application
      • 8.4.6.3.5. Market size and forecast, by End User
      • 8.4.6.4. India
      • 8.4.6.4.1. Key market trends, growth factors and opportunities
      • 8.4.6.4.2. Market size and forecast, by Product
      • 8.4.6.4.3. Market size and forecast, by Technology
      • 8.4.6.4.4. Market size and forecast, by Application
      • 8.4.6.4.5. Market size and forecast, by End User
      • 8.4.6.5. South Korea
      • 8.4.6.5.1. Key market trends, growth factors and opportunities
      • 8.4.6.5.2. Market size and forecast, by Product
      • 8.4.6.5.3. Market size and forecast, by Technology
      • 8.4.6.5.4. Market size and forecast, by Application
      • 8.4.6.5.5. Market size and forecast, by End User
      • 8.4.6.6. Rest of Asia-Pacific
      • 8.4.6.6.1. Key market trends, growth factors and opportunities
      • 8.4.6.6.2. Market size and forecast, by Product
      • 8.4.6.6.3. Market size and forecast, by Technology
      • 8.4.6.6.4. Market size and forecast, by Application
      • 8.4.6.6.5. Market size and forecast, by End User
  • 8.5. LAMEA
    • 8.5.1. Key trends and opportunities
    • 8.5.2. Market size and forecast, by Product
    • 8.5.3. Market size and forecast, by Technology
    • 8.5.4. Market size and forecast, by Application
    • 8.5.5. Market size and forecast, by End User
    • 8.5.6. Market size and forecast, by country
      • 8.5.6.1. Brazil
      • 8.5.6.1.1. Key market trends, growth factors and opportunities
      • 8.5.6.1.2. Market size and forecast, by Product
      • 8.5.6.1.3. Market size and forecast, by Technology
      • 8.5.6.1.4. Market size and forecast, by Application
      • 8.5.6.1.5. Market size and forecast, by End User
      • 8.5.6.2. Saudi Arabia
      • 8.5.6.2.1. Key market trends, growth factors and opportunities
      • 8.5.6.2.2. Market size and forecast, by Product
      • 8.5.6.2.3. Market size and forecast, by Technology
      • 8.5.6.2.4. Market size and forecast, by Application
      • 8.5.6.2.5. Market size and forecast, by End User
      • 8.5.6.3. South Africa
      • 8.5.6.3.1. Key market trends, growth factors and opportunities
      • 8.5.6.3.2. Market size and forecast, by Product
      • 8.5.6.3.3. Market size and forecast, by Technology
      • 8.5.6.3.4. Market size and forecast, by Application
      • 8.5.6.3.5. Market size and forecast, by End User
      • 8.5.6.4. Rest of LAMEA
      • 8.5.6.4.1. Key market trends, growth factors and opportunities
      • 8.5.6.4.2. Market size and forecast, by Product
      • 8.5.6.4.3. Market size and forecast, by Technology
      • 8.5.6.4.4. Market size and forecast, by Application
      • 8.5.6.4.5. Market size and forecast, by End User

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

  • 10.1. Thermo Fisher Scientific Inc.
    • 10.1.1. Company overview
    • 10.1.2. Key Executives
    • 10.1.3. Company snapshot
    • 10.1.4. Operating business segments
    • 10.1.5. Product portfolio
    • 10.1.6. Business performance
  • 10.2. Charles River Laboratories
    • 10.2.1. Company overview
    • 10.2.2. Key Executives
    • 10.2.3. Company snapshot
    • 10.2.4. Operating business segments
    • 10.2.5. Product portfolio
    • 10.2.6. Business performance
  • 10.3. Lonza
    • 10.3.1. Company overview
    • 10.3.2. Key Executives
    • 10.3.3. Company snapshot
    • 10.3.4. Operating business segments
    • 10.3.5. Product portfolio
    • 10.3.6. Business performance
  • 10.4. F. Hoffmann-La Roche Ltd.
    • 10.4.1. Company overview
    • 10.4.2. Key Executives
    • 10.4.3. Company snapshot
    • 10.4.4. Operating business segments
    • 10.4.5. Product portfolio
    • 10.4.6. Business performance
  • 10.5. Bio-Rad Laboratories, Inc.
    • 10.5.1. Company overview
    • 10.5.2. Key Executives
    • 10.5.3. Company snapshot
    • 10.5.4. Operating business segments
    • 10.5.5. Product portfolio
    • 10.5.6. Business performance
  • 10.6. Eurofins Scientific
    • 10.6.1. Company overview
    • 10.6.2. Key Executives
    • 10.6.3. Company snapshot
    • 10.6.4. Operating business segments
    • 10.6.5. Product portfolio
    • 10.6.6. Business performance
  • 10.7. ATCC
    • 10.7.1. Company overview
    • 10.7.2. Key Executives
    • 10.7.3. Company snapshot
    • 10.7.4. Operating business segments
    • 10.7.5. Product portfolio
  • 10.8. Bionique Testing Laboratories LLC
    • 10.8.1. Company overview
    • 10.8.2. Key Executives
    • 10.8.3. Company snapshot
    • 10.8.4. Operating business segments
    • 10.8.5. Product portfolio
  • 10.9. InvivoGen
    • 10.9.1. Company overview
    • 10.9.2. Key Executives
    • 10.9.3. Company snapshot
    • 10.9.4. Operating business segments
    • 10.9.5. Product portfolio
  • 10.10. Norgen Biotek Corp.
    • 10.10.1. Company overview
    • 10.10.2. Key Executives
    • 10.10.3. Company snapshot
    • 10.10.4. Operating business segments
    • 10.10.5. Product portfolio

LIST OF TABLES

  • TABLE 01. GLOBAL MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 02. MYCOPLASMA TESTING MARKET FOR INSTRUMENTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. MYCOPLASMA TESTING MARKET FOR KITS AND REAGENTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. MYCOPLASMA TESTING MARKET FOR SERVICES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 06. MYCOPLASMA TESTING MARKET FOR PCR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. MYCOPLASMA TESTING MARKET FOR ELISA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. MYCOPLASMA TESTING MARKET FOR MICROBIAL CULTURE TECHNIQUES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. MYCOPLASMA TESTING MARKET FOR ENZYMATIC METHODS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 11. MYCOPLASMA TESTING MARKET FOR CELL LINE TESTING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. MYCOPLASMA TESTING MARKET FOR VIRUS TESTING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. MYCOPLASMA TESTING MARKET FOR END OF PRODUCTION CELLS TESTING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. MYCOPLASMA TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 16. MYCOPLASMA TESTING MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. MYCOPLASMA TESTING MARKET FOR CELL BANKS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. MYCOPLASMA TESTING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. MYCOPLASMA TESTING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. MYCOPLASMA TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. MYCOPLASMA TESTING MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 23. NORTH AMERICA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 24. NORTH AMERICA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 25. NORTH AMERICA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 26. NORTH AMERICA MYCOPLASMA TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 27. U.S. MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 28. U.S. MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 29. U.S. MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 30. U.S. MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 31. CANADA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 32. CANADA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 33. CANADA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 34. CANADA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 35. MEXICO MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 36. MEXICO MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 37. MEXICO MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 38. MEXICO MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 39. EUROPE MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 40. EUROPE MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 41. EUROPE MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 42. EUROPE MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. EUROPE MYCOPLASMA TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 44. GERMANY MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 45. GERMANY MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 46. GERMANY MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 47. GERMANY MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 48. FRANCE MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 49. FRANCE MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 50. FRANCE MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 51. FRANCE MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. UK MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 53. UK MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 54. UK MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 55. UK MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 56. ITALY MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 57. ITALY MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 58. ITALY MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 59. ITALY MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 60. SPAIN MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 61. SPAIN MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 62. SPAIN MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 63. SPAIN MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 64. REST OF EUROPE MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 65. REST OF EUROPE MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 66. REST OF EUROPE MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 67. REST OF EUROPE MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 68. ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 69. ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 70. ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 71. ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 72. ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 73. JAPAN MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 74. JAPAN MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 75. JAPAN MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 76. JAPAN MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 77. CHINA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 78. CHINA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 79. CHINA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 80. CHINA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 81. AUSTRALIA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 82. AUSTRALIA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 83. AUSTRALIA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 84. AUSTRALIA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 85. INDIA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 86. INDIA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 87. INDIA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 88. INDIA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 89. SOUTH KOREA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 90. SOUTH KOREA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 91. SOUTH KOREA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 92. SOUTH KOREA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 93. REST OF ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 94. REST OF ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 95. REST OF ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 96. REST OF ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 97. LAMEA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 98. LAMEA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 99. LAMEA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 100. LAMEA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 101. LAMEA MYCOPLASMA TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 102. BRAZIL MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 103. BRAZIL MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 104. BRAZIL MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 105. BRAZIL MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 106. SAUDI ARABIA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 107. SAUDI ARABIA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 108. SAUDI ARABIA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 109. SAUDI ARABIA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 110. SOUTH AFRICA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 111. SOUTH AFRICA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 112. SOUTH AFRICA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 113. SOUTH AFRICA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 114. REST OF LAMEA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 115. REST OF LAMEA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 116. REST OF LAMEA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 117. REST OF LAMEA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 118. THERMO FISHER SCIENTIFIC INC. : KEY EXECUTIVES
  • TABLE 119. THERMO FISHER SCIENTIFIC INC. : COMPANY SNAPSHOT
  • TABLE 120. THERMO FISHER SCIENTIFIC INC. : PRODUCT SEGMENTS
  • TABLE 121. THERMO FISHER SCIENTIFIC INC. : SERVICE SEGMENTS
  • TABLE 122. THERMO FISHER SCIENTIFIC INC. : PRODUCT PORTFOLIO
  • TABLE 123. CHARLES RIVER LABORATORIES: KEY EXECUTIVES
  • TABLE 124. CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
  • TABLE 125. CHARLES RIVER LABORATORIES: SERVICE SEGMENTS
  • TABLE 126. CHARLES RIVER LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 127. LONZA: KEY EXECUTIVES
  • TABLE 128. LONZA: COMPANY SNAPSHOT
  • TABLE 129. LONZA: PRODUCT SEGMENTS
  • TABLE 130. LONZA: SERVICE SEGMENTS
  • TABLE 131. LONZA: PRODUCT PORTFOLIO
  • TABLE 132. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 133. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 134. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 135. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 136. BIO-RAD LABORATORIES, INC. : KEY EXECUTIVES
  • TABLE 137. BIO-RAD LABORATORIES, INC. : COMPANY SNAPSHOT
  • TABLE 138. BIO-RAD LABORATORIES, INC. : PRODUCT SEGMENTS
  • TABLE 139. BIO-RAD LABORATORIES, INC. : PRODUCT PORTFOLIO
  • TABLE 140. EUROFINS SCIENTIFIC: KEY EXECUTIVES
  • TABLE 141. EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
  • TABLE 142. EUROFINS SCIENTIFIC: SERVICE SEGMENTS
  • TABLE 143. EUROFINS SCIENTIFIC: PRODUCT PORTFOLIO
  • TABLE 144. ATCC: KEY EXECUTIVES
  • TABLE 145. ATCC: COMPANY SNAPSHOT
  • TABLE 146. ATCC: PRODUCT SEGMENTS
  • TABLE 147. ATCC: SERVICE SEGMENTS
  • TABLE 148. ATCC: PRODUCT PORTFOLIO
  • TABLE 149. BIONIQUE TESTING LABORATORIES LLC: KEY EXECUTIVES
  • TABLE 150. BIONIQUE TESTING LABORATORIES LLC: COMPANY SNAPSHOT
  • TABLE 151. BIONIQUE TESTING LABORATORIES LLC: PRODUCT SEGMENTS
  • TABLE 152. BIONIQUE TESTING LABORATORIES LLC: SERVICE SEGMENTS
  • TABLE 153. BIONIQUE TESTING LABORATORIES LLC: PRODUCT PORTFOLIO
  • TABLE 154. INVIVOGEN: KEY EXECUTIVES
  • TABLE 155. INVIVOGEN: COMPANY SNAPSHOT
  • TABLE 156. INVIVOGEN: PRODUCT SEGMENTS
  • TABLE 157. INVIVOGEN: SERVICE SEGMENTS
  • TABLE 158. INVIVOGEN: PRODUCT PORTFOLIO
  • TABLE 159. NORGEN BIOTEK CORP.: KEY EXECUTIVES
  • TABLE 160. NORGEN BIOTEK CORP.: COMPANY SNAPSHOT
  • TABLE 161. NORGEN BIOTEK CORP.: PRODUCT SEGMENTS
  • TABLE 162. NORGEN BIOTEK CORP.: SERVICE SEGMENTS
  • TABLE 163. NORGEN BIOTEK CORP.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. MYCOPLASMA TESTING MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF MYCOPLASMA TESTING MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN MYCOPLASMA TESTING MARKET (2023-2032)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 08. HIGH INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALMYCOPLASMA TESTING MARKET
  • FIGURE 10. MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR INSTRUMENTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR KITS AND REAGENTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR SERVICES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR PCR, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR ELISA, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR MICROBIAL CULTURE TECHNIQUES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR ENZYMATIC METHODS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR CELL LINE TESTING, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR VIRUS TESTING, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR END OF PRODUCTION CELLS TESTING, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. MYCOPLASMA TESTING MARKET, BY END USER, 2022(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR CELL BANKS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 27. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 28. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 29. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 30. MYCOPLASMA TESTING MARKET BY REGION, 2022
  • FIGURE 31. U.S. MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. CANADA MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. MEXICO MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. GERMANY MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. FRANCE MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. UK MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. ITALY MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. SPAIN MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. REST OF EUROPE MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. JAPAN MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. CHINA MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. AUSTRALIA MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. INDIA MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. SOUTH KOREA MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. REST OF ASIA-PACIFIC MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. BRAZIL MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 47. SAUDI ARABIA MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 48. SOUTH AFRICA MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 49. REST OF LAMEA MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 50. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 51. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 52. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 53. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 54. COMPETITIVE DASHBOARD
  • FIGURE 55. COMPETITIVE HEATMAP: MYCOPLASMA TESTING MARKET
  • FIGURE 56. TOP PLAYER POSITIONING, 2022
  • FIGURE 57. THERMO FISHER SCIENTIFIC INC. : NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 58. THERMO FISHER SCIENTIFIC INC. : REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 59. THERMO FISHER SCIENTIFIC INC. : REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 60. CHARLES RIVER LABORATORIES: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 61. CHARLES RIVER LABORATORIES: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 62. CHARLES RIVER LABORATORIES: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 63. LONZA: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 64. LONZA: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 65. LONZA: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 66. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 67. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 68. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 69. BIO-RAD LABORATORIES, INC. : NET SALES, 2020-2022 ($MILLION)
  • FIGURE 70. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 71. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 72. EUROFINS SCIENTIFIC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 73. EUROFINS SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2021 (%)